- Email: [email protected]
Latest Advance and Future Perspective for the Treatment of Metastatic Colorectal Cancer (mCRC)
Annals of Oncology 30 (Supplement 6): vi59, 2019 doi:10.1093/annonc/mdz365
EDUCATIONAL LECTURE 17 : LATEST ADVANCE AND FUTURE PERSPECTIVE FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) EL17
Latest Advance and Future Perspective for the Treatment of Metastatic Colorectal Cancer (mCRC)
Several cancer genome alterations have been identified as important targets for mCRC treatment, which include BRAF mutation, HER-2 amplification/expression, microsatellite instability-high (MSI-H) and etc., for which corresponding agents showed promising activity in clinical trials. In addition, emerging concept in clinical development targeting microsatellite stable (MSS) mCRC comes into question which compound adding on an immune checkpoint inhibitor evokes immunity. Successful combination strategy evoking immunity will break out of the paradigm.
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz365/5582918 by guest on 25 October 2019
Takayuki Yoshino Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East
Current clinical development of corresponding agents in molecularly characterized cohorts of cancer patients as well as in acquired targets by means of NGS- and bloodbased molecular testing may represent more substantial progress toward precision medicine. We initiated the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN) since 2015 to detect orphan-fractionated cancer subtypes. In addition, we also launched circulating tumor DNA (ctDNA) analysis-based cancer genome screening project since February 2018. On the basis of cancer genome alterations by NGS- and blood-based molecular testing, umbrella & basket-type investigator-initiated clinical trials with the National Patient Registry are anticipated to contribute to the establishment of the appropriate infrastructure in terms of the promotion of clinical development for orphan-fractionated cancer subtypes, which are regarded as having the low priority for pharmaceutical companies, but as having the high priority for cancer patients.
EDUCATIONAL LECTURE 17 : LATEST ADVANCE AND FUTURE PERSPECTIVE FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) EL17
Latest Advance and Future Perspective for the Treatment of Metastatic Colorectal Cancer (mCRC)
Several cancer genome alterations have been identified as important targets for mCRC treatment, which include BRAF mutation, HER-2 amplification/expression, microsatellite instability-high (MSI-H) and etc., for which corresponding agents showed promising activity in clinical trials. In addition, emerging concept in clinical development targeting microsatellite stable (MSS) mCRC comes into question which compound adding on an immune checkpoint inhibitor evokes immunity. Successful combination strategy evoking immunity will break out of the paradigm.
C The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. V
All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_6/mdz365/5582918 by guest on 25 October 2019
Takayuki Yoshino Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East
Current clinical development of corresponding agents in molecularly characterized cohorts of cancer patients as well as in acquired targets by means of NGS- and bloodbased molecular testing may represent more substantial progress toward precision medicine. We initiated the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN) since 2015 to detect orphan-fractionated cancer subtypes. In addition, we also launched circulating tumor DNA (ctDNA) analysis-based cancer genome screening project since February 2018. On the basis of cancer genome alterations by NGS- and blood-based molecular testing, umbrella & basket-type investigator-initiated clinical trials with the National Patient Registry are anticipated to contribute to the establishment of the appropriate infrastructure in terms of the promotion of clinical development for orphan-fractionated cancer subtypes, which are regarded as having the low priority for pharmaceutical companies, but as having the high priority for cancer patients.